The effect of antigen dose on T cell-targeting vaccine outcome

• 主要な著者: Rolf Billeskov (著者), Babak Beikzadeh (著者), Jay A. Berzofsky (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2019-02-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.
• Notes: 2164-5515; 2164-554X; 10.1080/21645515.2018.1527496
• Keywords: antigen dose; t cell; stimulation strength; t cell receptor; vaccine; infectious immunity; protection; Immunologic diseases. Allergy; RC581-607; Therapeutics. Pharmacology; RM1-950
• Source: Human Vaccines & Immunotherapeutics, Vol 15, Iss 2, Pp 407-411 (2019)

During the past 3-4 decades, an increasing amount of evidence has pointed to the complex role of the antigen dose or T cell receptor (TCR) stimulation strength on the subsequent type, duration and "flavor" or quality of the response. Antigen dose was initially shown to impact Th1/Th2 bias, and later also shown to differentially affect development and induction of Tregs, Th17, T-follicular helper (Tfh), cells, and others. In recent years the quality of both CD4/8 T cells during infections, cancer and/or autoimmunity has turned out to be critical for subsequent disease outcome. Importantly, different vaccination strategies also lead to different types of T cell responses, and the role of the antigen dose is emerging as an important factor as well as a tool for investigators to utilize in fine-tuning vaccine efficacy. This commentary will highlight essential background of how antigen dose can impact and affect the quality of T cell responses, and discuss how this translates in different vaccine settings.